The FDA has approved the oral PARP inhibitor talazoparib plus enzalutamide to treat homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.
Pfizer also noted that a marketing authorization application for the drug combination has been accepted for review by the European Medicines Agency.
"Despite treatment advancement in metastatic castration-resistant prostate cancer, the disease can progress quickly, and many patients may only receive one line of therapy," lead investigator Neeraj Agarwal, MD, of the Huntsman Cancer Institute, University of Utah,.
Sharon Worcester, MA, is an award-winning medical journalist based in Birmingham, Alabama, writing for Medscape, MDedge and other affiliate sites. She currently covers oncology, but she has also written on a variety of other medical specialties and healthcare topics. She can be reached at
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
San Diego city auditor one step closer to being allowed to hire his own lawyerCity Council approves measure 5-4; voters expected to weigh in in primary or general election
Read more »
FDA OKs Drug for Cholestatic Pruritus in Alagille SyndromeOdevixibat is indicated for treatment of cholestatic pruritus associated with Alagille syndrome in patients as young as 12 months. It marks the second indication for the drug.
Read more »
FDA OKs Low-Dose Colchicine for Broad CV IndicationThe drug represents the first specific anti-inflammatory drug for the reduction of cardiovascular events for patients with established atherosclerotic disease or with multiple risk factors.
Read more »
FDA Warns of Tattoo Ink Tied to Dangerous InfectionsThe FDA released the new draft guidance aiming to reduce the use of pathogen-contaminated tattoo ink, which can cause stubborn infections that are especially hard to treat, dermatologists said.
Read more »
FDA OKs Empagliflozin for Children With Type 2 DiabetesThe FDA has approved empagliflozin and empagliflozin combined with metformin for the treatment of type 2 diabetes in children aged 10 years and older.
Read more »
Spain registers record asylum claims, approves far fewer than European averageSpain received a record number of claims for refugee status and international protection last year, but the government rejects far more applications than the European average, a nongovernmental organization said Monday.
Read more »